Read by QxMD icon Read

International Journal of Clinical Oncology

Koji Ando, Yasunori Emi, Toyokuni Suenaga, Masahiro Hamanoue, Soichiro Maekawa, Yasuo Sakamoto, Seiichiro Kai, Hironaga Satake, Takayuki Shimose, Mototsugu Shimokawa, Hiroshi Saeki, Eiji Oki, Kenji Sakai, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara
BACKGROUND: This study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent colorectal cancer (CRC). METHODS: This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated unresectable or recurrent CRC, presence of measurable lesions, ≥20 years of age, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function...
May 19, 2017: International Journal of Clinical Oncology
Mustafa Erkan Sari, İbrahim Yalcin, Hanifi Sahin, Mehmet Mutlu Meydanli, Tayfun Gungor
OBJECTIVE: The purpose of this study was to determine the risk factors for paraaortic lymph node (LN) metastasis in endometrial cancer (EC) patients who underwent comprehensive surgical staging. METHODS: A total of 641 women with EC (endometrioid, non-endometrioid, or mixed histology) who underwent comprehensive surgical staging including pelvic and paraaortic LN dissection between 2008 and 2016 were included in this retrospective study. Patient data were analyzed with respect to paraaortic LN involvement, and predictive factors for paraaortic LN metastasis were investigated...
May 18, 2017: International Journal of Clinical Oncology
Katsutoshi Oda, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori-Uchino, Yutaka Osuga, Tomoyuki Fujii
Poly (ADP-ribose) polymerase (PARP) inhibitors have attracted much attention as one of the major molecular-targeted therapeutics for inhibiting DNA damage response. The PARP inhibitor, olaparib, has been clinically applied for treating certain recurrent ovarian cancer patients with BRCA1/2 mutations in Europe and the United States. It was also designated on 24 March 2017 as an orphan drug in Japan for similar clinical indications. In this review, we discuss (i) the prevalence of BRCA1/2 mutations in ovarian cancer, (ii) clinical trials of PARP inhibitors in ovarian cancer, (iii) genetic counseling for hereditary breast and ovarian cancer patients, and (iv) non-BRCA genes that may be associated with homologous recombination deficiency...
May 15, 2017: International Journal of Clinical Oncology
Ryoko Rikitake, Mizuo Ando, Yuki Saito, Seiichi Yoshimoto, Tatsuya Yamasoba, Takahiro Higashi
BACKGROUND: To investigate the status and treatment of superficial pharyngeal squamous cell carcinoma in Japan. METHODS: We analyzed all cases diagnosed between 2011 and 2013, as recorded in the national database of hospital-based cancer registries. We extracted data on patient sex, age, tumor locations, histology, presentation routes, initial treatments, and TNM stages. Additionally, we compared the characteristics of pharyngeal carcinoma to those of esophageal cancer...
May 13, 2017: International Journal of Clinical Oncology
Takuma Ohashi, Shuhei Komatsu, Daisuke Ichikawa, Toshiyuki Kosuga, Kazuma Okamoto, Tomohiro Arita, Hirotaka Konishi, Ryo Morimura, Yasutoshi Murayama, Atsushi Shiozaki, Yoshiaki Kuriu, Hisashi Ikoma, Masayoshi Nakanishi, Hitoshi Fujiwara, Eigo Otsuji
BACKGROUND: There is no evidence that monitoring tumor dynamics using sensitive tumor markers contributes to treatment decision-making and prognosis in gastric cancer patients with tumor recurrence. This study was designed to investigate the significance of tumor markers in monitoring peritoneal recurrence of gastric cancer. METHODS: We retrospectively analysed 102 consecutive patients who developed recurrence after curative gastrectomy for gastric cancer at our institute between 2002 and 2011...
May 9, 2017: International Journal of Clinical Oncology
Yanchen Ren, Yiyuan Cao, Weidong Hu, Xiaoxuan Wei, Xiaoyan Shen
BACKGROUND: To evaluate the computed tomography features of peripheral small cell lung cancer and non-small cell lung cancer and to establish a predictive model to conveniently distinguish between them. MATERIALS AND METHODS: We retrospectively reviewed the computed tomography features of 51 patients with peripheral small cell lung cancer and 207 patients with peripheral non-small cell lung cancer after pathological diagnosis. Thirteen computed tomography morphologic findings were included and analyzed statistically...
May 9, 2017: International Journal of Clinical Oncology
Zunyong Liu, Yan Xu, Zhong-Liang Liu, Yi-Zhou Tian, Xiao-Heng Shen
BACKGROUND: Metastatic bone cancer pain is one of the most common clinical cancer pains and is caused by many factors. This study was conducted to explore the clinical efficacy of using two non-steroidal anti-inflammatory drugs (NSAIDs) along with an opioid in treating metastatic bone cancer pain. MATERIAL AND METHOD: A total of 342 patients with a pain score of 7-10 on the visual analog scale (VAS) were recruited for 4 weeks of treatment and randomly assigned to three different groups-one group received two NSAIDs (diclofenac and celecoxib), one group received diclofenac, and one group received celecoxib...
May 8, 2017: International Journal of Clinical Oncology
Hiroji Uemura, Hirotsugu Uemura, Nobuaki Matsubara, Seigo Kinuya, Makoto Hosono, Yoko Yajima, Toshihiko Doi
BACKGROUND: Radiation therapy with radium-223 dichloride improves overall survival, reduces symptomatic skeletal events in Caucasian patients with castration-resistant prostate cancer (CRPC) and bone metastases, and is well tolerated. We report here the results of the first efficacy and safety study of radium-223 dichloride in a Japanese population. METHODS: In this open-label, uncontrolled, non-randomized, phase I trial, radium-223 dichloride was given to Japanese patients with CRPC and ≥2 bone metastases in 4-week cycles...
May 6, 2017: International Journal of Clinical Oncology
Yi-Jun Kim, Hyeon Kang Koh, Eui Kyu Chie, Do-Youn Oh, Yung-Jue Bang, Eun Mi Nam, Kyubo Kim
PURPOSE: To investigate the significance of carbohydrate antigen 19-9 (CA19-9) levels for survival in locally advanced pancreatic cancer (LAPC) treated with concurrent chemoradiotherapy (CCRT). METHODS/PATIENTS: We retrospectively reviewed data from 97 LAPC patients treated with CCRT between 2000 and 2013. CA19-9 levels (initial and post-CCRT) and their changes [{(post-CCRT CA19-9 level - initial CA19-9 level)/(initial CA19-9 level)} × 100] were analyzed for overall survival...
May 5, 2017: International Journal of Clinical Oncology
Tomoki Kimura, Yasushi Nagata, Hideyuki Harada, Shinya Hayashi, Yukinori Matsuo, Tsuyoshi Takanaka, Masaki Kokubo, Kenji Takayama, Hiroshi Onishi, Koichi Hirakawa, Yoshiyuki Shioyama, Takeshi Ehara
BACKGROUND: To investigate the maximum tolerated dose (MTD) and recommended dose (RD) of stereotactic body radiation therapy (SBRT) for centrally located stage IA non-small cell lung cancer (NSCLC). METHODS: Five dose levels, ranging from of 52 to 68 Gy in eight fractions, were determined; the treatment protocol began at 60 Gy (level 3). Each dose level included 10 patients. Levels 1-2 were indicated if more than four patients exhibited dose-limiting toxicity (DLT), which was defined as an occurrence of a grade 3 (or worse) adverse effect within 12 months after SBRT initiation...
May 2, 2017: International Journal of Clinical Oncology
Kazuki Kano, Toru Aoyama, Yukio Maezawa, Tetsushi Nakajima, Kosuke Ikeda, Takanobu Yamada, Tsutomu Sato, Takashi Oshima, Yasushi Rino, Munetaka Masuda, Takashi Ogata, Haruhiko Cho, Takaki Yoshikawa
BACKGROUND: Upfront surgery and subsequent S-1 chemotherapy is frequently selected for peritoneal cytology-positive (CY1) gastric cancer patients without other distant metastases (CY1-only). The objective of this study was to confirm the efficacy of this strategy in clinical practice and to identify the risk factors associated with survival. METHODS: Overall survival (OS) and recurrence-free survival (RFS) were examined in 36 CY1-only patients who underwent macroscopic curative resection followed by postoperative S-1 chemotherapy between January 2000 and June 2015...
April 29, 2017: International Journal of Clinical Oncology
Erfan Ayubi, Saeid Safiri
No abstract text is available yet for this article.
April 28, 2017: International Journal of Clinical Oncology
Yusuke Tanaka, Yutaka Ueda, Mamoru Kakuda, Satoshi Kubota, Satoko Matsuzaki, Tadashi Iwamiya, Akiko Okazawa, Shinya Matsuzaki, Kae Hashimoto, Eiji Kobayashi, Seiji Mabuchi, Kenjiro Sawada, Takuji Tomimatsu, Kiyoshi Yoshino, Tadashi Kimura
OBJECTIVE: The objective of the study is to identify the risk factors associated with recurrent/persistent disease and cervical stenosis after conization. METHODS: Five hundred twenty-two (522) cases of high-grade intraepithelial lesions treated by conization were retrospectively reviewed. Risk factors associated with recurrent/persistent disease were analyzed by univariate and multivariate analysis using a Cox hazard regression model. Factors that could potentially affect the risk of cervical stenosis were examined by univariate and by multivariate analysis using the χ (2) test and logistic regression, respectively...
April 27, 2017: International Journal of Clinical Oncology
Teruhisa Takuwa, Masaki Hashimoto, Seiji Matsumoto, Nobuyuki Kondo, Kozo Kuribayash, Takashi Nakano, Seiki Hasegawa
BACKGROUND: Additional chemotherapy is often not feasible in patients with recurrent malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP), due to deteriorated cardiopulmonary reserve. We thus examined the feasibility and efficacy of additional chemotherapy in patients with recurrent MPM after EPP. METHODS: A retrospective review was conducted of 59 consecutive patients who underwent bi-/tri-modal treatment with induction chemotherapy, EPP, and radiation therapy from July 2004 to August 2013 at Hyogo College of Medicine (Nishinomiya, Japan)...
April 24, 2017: International Journal of Clinical Oncology
Hiromitsu Iwata, Satoshi Ishikura, Taro Murai, Michio Iwabuchi, Mitsuhiro Inoue, Koshi Tatewaki, Seiji Ohta, Naoki Yokota, Yuta Shibamoto
BACKGROUND: In this phase I/II study, we assessed the safety and initial efficacy of stereotactic body radiotherapy (SBRT) for lung tumors with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm. METHODS: Study subjects had histologically confirmed primary non-small-cell lung cancer staged as T1a-T2aN0M0 and pulmonary oligometastasis. The primary endpoint was the incidence of Grade ≥3 radiation pneumonitis (RP) within 180 days of the start of SBRT...
April 20, 2017: International Journal of Clinical Oncology
H Sasaki, K Tamura, Y Naito, K Ogata, A Mogi, T Tanaka, Y Ikari, M Masaki, Y Nakashima, Y Takamatsu
BACKGROUND: Cancer chemotherapy is associated with a variety of side effects/adverse events. It is very important that patients adhere to the planned chemotherapy regimen, which necessitates a minimum of side effects and that these side effects be kept under control. We have investigated patients' concerns and symptoms during chemotherapy with the aim to seek solutions that will improve patients' quality of life during chemotherapy. METHODS: Forty-nine patients with malignant diseases on parenteral antineoplastic agents were sequentially enrolled in this study...
April 6, 2017: International Journal of Clinical Oncology
Takeshi Yuasa, Hitoshi Masuda, Shinya Yamamoto, Noboru Numao, Junji Yonese
Nivolumab is a fully human immunoglobulin (Ig) G4 antibody that selectively inhibits the programmed death 1 (PD-1) immune checkpoint molecule, and has recently been launched for the treatment of renal cell cancer (RCC) in Japan. Based on its promising anti-tumor efficacy and manageable safety profile demonstrated in the phase III Checkmate 025 trial, nivolumab therapy is rapidly being introduced in metastatic RCC clinical practice. The phase Ia study of atezolizumab, which is a humanized anti-PD-ligand 1 (PD-L1) monoclonal IgG1 antibody, also demonstrated excellent treatment results...
April 5, 2017: International Journal of Clinical Oncology
Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Toshiaki Takahashi
BACKGROUND: Currently, no markers predictive of response to nivolumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) are currently recognized in Japan. The present study was undertaken to identify such markers. MATERIALS AND METHODS: Medical records of 50 patients with advanced NSCLC and treated with nivolumab monotherapy at Shizuoka Cancer Center between December 2015 and April 2016 were retrospectively reviewed. The parameters studied were age, sex, Eastern Cooperative Oncology Group performance status, smoking history, histological diagnosis, epidermal growth factor receptor or anaplastic lymphoma kinase status, therapeutic line of nivolumab, efficacy of treatment immediately before nivolumab monotherapy, and time since previous therapy...
April 5, 2017: International Journal of Clinical Oncology
Hironori Fukuda, Tsunenori Kondo, Toshio Takagi, Jumpei Iizuka, Yoji Nagashima, Kazunari Tanabe
BACKGROUND: The clinical benefit of targeted molecular therapy (TMT) for an inferior vena cava (IVC) tumor thrombus associated with renal cell carcinoma (RCC) is unclear. The aim of the present study was to assess the change in IVC thrombus height during TMT and to identify the factors associated with the effect of TMT on an IVC thrombus in RCC patients. METHODS: The present study retrospectively analyzed 21 patients with an IVC thrombus who were treated with TMT at our hospital...
April 1, 2017: International Journal of Clinical Oncology
Taku Maeda, Yuhei Yamamoto, Hiroshi Furukawa, Akihiko Oyama, Emi Funayama, Naoki Murao, Toshihiko Hayashi
BACKGROUND: The purpose of this study was to evaluate the superficial lymph drainage patterns of primary skin cancers of the head arising from the occipital or parietal region. METHODS: The dominant patterns of lymph drainage were retrospectively reviewed in eight patients aged 36-85 years with skin cancers in the occipital or parietal region in whom sentinel lymph node biopsy or lymph node dissection had been performed at Hokkaido University Hospital between January 1981 and December 2015...
March 31, 2017: International Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"